Acta Pharmaceutica Sinica B : Impact Factor & More
eISSN: 2211-3843pISSN: 2211-3835
Open AccessShare this on:
Key Metrics
CiteScore 
15.9
Eigenfactor
< 0.001
Impact Factor
10 - 15
Scite Index
0.95 5-Year SI
SJR
Q1Pharmacology, Toxicology and Pharmaceutics (all)
SNIP
2.59
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
Topics Covered on Acta Pharmaceutica Sinica B
Acta Pharmaceutica Sinica B Journal Specifications
| Overview | |
| Publisher | INST MATERIA MEDICA, CHINESE ACAD MEDICAL SCIENCES |
| Language | English |
| Frequency | Bi-monthly |
| Publication Time | 19 |
| Editorial Review Process | Anonymous peer review |
| General Details | |
| Language | English |
| Society/Institute/Sponsor | Insititute of Materia Medica, Chinese Academy of Medical Sciences and Chinese Pharmaceutical Association |
| Frequency | Bi-monthly |
| Publication Start Year | 2011 |
| Website URL | Visit website |
| Publication Details | |
| Editorial Review Detail | |
| Information for authors | |
| Author instructions | Visit website |
| Deposit Policy | Sherpa/Romeo |
| License type | CC BY, CC BY-NC-ND |
| OA statement | Visit website |
View less
Planning to publish in Acta Pharmaceutica Sinica B ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in Acta Pharmaceutica Sinica B
Advanced drug delivery platforms targeting cellular senescence: A promising strategy for cancer therapy
- 1 Apr 2026
- Acta Pharmaceutica Sinica B
Editorial of special column of hot topic reviews in drug delivery (II).
- 1 Apr 2026
- Acta pharmaceutica Sinica. B
Metabolic-epigenetic reprogramming via the PLOD1–PFKP axis drives cisplatin resistance in HNSCC
- 1 Apr 2026
- Acta Pharmaceutica Sinica B
Targeting frizzled receptors (FZDs) for anti-tumor therapy: From orthosteric to allosteric inhibition
- 1 Apr 2026
- Acta Pharmaceutica Sinica B
Targeted nanoparticles with triggered lysosomal escape enable anti-angiogenic immunotherapy for peritoneal metastatic colorectal cancer
- 1 Apr 2026
- Acta Pharmaceutica Sinica B
Insights into SARS-CoV-2 replication control via targeting the host hijacking function of NSP12
- 1 Apr 2026
- Acta Pharmaceutica Sinica B
Advanced drug delivery platforms targeting cellular senescence: A promising strategy for cancer therapy
- 1 Apr 2026
- Acta Pharmaceutica Sinica B
Editorial of special column of hot topic reviews in drug delivery (II).
- 1 Apr 2026
- Acta pharmaceutica Sinica. B
Metabolic-epigenetic reprogramming via the PLOD1–PFKP axis drives cisplatin resistance in HNSCC
- 1 Apr 2026
- Acta Pharmaceutica Sinica B
Targeting frizzled receptors (FZDs) for anti-tumor therapy: From orthosteric to allosteric inhibition
- 1 Apr 2026
- Acta Pharmaceutica Sinica B
Targeted nanoparticles with triggered lysosomal escape enable anti-angiogenic immunotherapy for peritoneal metastatic colorectal cancer
- 1 Apr 2026
- Acta Pharmaceutica Sinica B
Insights into SARS-CoV-2 replication control via targeting the host hijacking function of NSP12
- 1 Apr 2026
- Acta Pharmaceutica Sinica B
FAQs on Acta Pharmaceutica Sinica B
How long has Acta Pharmaceutica Sinica B been actively publishing? 
What is the publishing frequency of Acta Pharmaceutica Sinica B?
How many articles did Acta Pharmaceutica Sinica B publish last year?
What is the eISSN & pISSN for Acta Pharmaceutica Sinica B?
What is Citescore for Acta Pharmaceutica Sinica B?
What is SNIP score for Acta Pharmaceutica Sinica B?
What is the SJR for Acta Pharmaceutica Sinica B?
Who is the publisher of Acta Pharmaceutica Sinica B?
